Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

Kumi OshimaDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Miki SatoDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Shinya OkudaDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Kiriko TerasakoDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Hideki NakasoneDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Shinichi KakoDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Rie YamazakiDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Yukie TanakaDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Aki TaniharaDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Takakazu HiguchiDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Junji NishidaDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Ikuo NakamuraDivision of GastroenterologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Yukio YoshidaDivision of GastroenterologySaitama Medical Center, Jichi Medical University, Saitama, Japan

Yoshinobu KandaDivision of HematologySaitama Medical Center, Jichi Medical University, Saitama, Japan

show all

Abstract

The appearance of hepatitis B surface antigen (HBsAg) in patients previously positive for antibody to this antigen (HBsAb) is called reverse seroconversion, a rare complication after hematopoietic stem cell transplantation (HSCT), which occurs almost exclusively after HSCT from an HBsAb-negative donor and the development of chronic graft-versus-host disease (CGVHD). However, we experienced a patient who developed reverse seroconversion 23 months after unrelated HSCT even in the absence of immunosuppressants use or CGVHD. Serum immunoglobulin level was persistently normal. Therefore, all HBsAb-positive recipients should be considered to be at risk for HBV reactivation, even in patients without any risk factors.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

Information for

Open access

Opportunities

Help and information

Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature